Urotronic Inc.
11
4
6
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
9.1%
1 terminated/withdrawn out of 11 trials
75.0%
-11.5% vs industry average
9%
1 trials in Phase 3/4
133%
4 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
Role: lead
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
Role: lead
EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures
Role: lead
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
Role: lead
Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
Role: lead
Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter
Role: lead
ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
Role: lead
Optilume™ BPH Catheter System in Men With Symptomatic BPH
Role: lead
ROBUST I Pilot Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
Role: lead
Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)
Role: collaborator
Re-Establishing Flow Via Drug Coated Balloon for the Treatment of Urethral Stricture Disease - Registry Study
Role: lead
All 11 trials loaded